# DELIVERING FOR A CLEANER, HEALTHIER WORLD

**FY 2023 RESULTS** 



#### **DISCLAIMER**

#### Cautionary note concerning forward-looking statements

This presentation contains statements with respect to the financial condition, results of operations and business of Reckitt Benckiser Group plc and the Reckitt group of companies (the "Group") and certain of the plans and objectives of the Group that are forward-looking statements. Words such as 'intends', 'targets', or the negative of these terms and other similar expressions of future performance or results, and their negatives, are intended to identify such forward-looking statements. In particular, all statements that express forecasts, expectations and projections with respect to future matters, including targets for net revenue, operating margin and cost efficiency, are forward-looking statements. Such statements are not historical facts, nor are they guarantees of future.

By their nature, forward-looking statements involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future. There are a number of factors that could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements, including many factors outside the Group's control. Among other risks and uncertainties, the material or principal factors which could cause actual results to differ materially are: the general economic, business, political, geopolitical and social conditions in the key markets in which the Group operates; the Group's ability to innovate and remain competitive; the Group's investment choices in its portfolio management; the ability of the Group to address existing and emerging

environmental and social risks and opportunities; the ability of the Group to manage regulatory, tax and legal matters, including changes thereto; the reliability of the Group's technological infrastructure or that of third parties on which the Group relies; interruptions in the Group's supply chain and disruptions to its production facilities; increases or volatility in the cost of raw materials and commodities; the execution of acquisitions, divestitures and business transformation projects; the reputation of the Group's global brands; and the recruitment and retention of key management.

These forward-looking statements speak only as of the date of this announcement. Except as required by any applicable law or regulation, the Group expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the Group's expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.

Further details of potential risks and uncertainties affecting the Group are described in the Group's filings with the London Stock Exchange, including in the Reckitt Annual Report and Accounts 2022.



# **KRIS LICHT**

**Chief Executive Officer** 



## **AGENDA**



Key messages



Financial review and outlook

## **KEY MESSAGES**



A year of progress in 2023



**Clear priorities** 



**Enduring framework** for value creation

#### 2023 - A YEAR OF PROGRESS



Good trading performance in Health and Hygiene



Innovation platforms prove they can deliver meaningful growth through premiumisation, household penetration and category creation



Gross margins returned to historical levels



Increased investments behind our brands and innovations



Fixed cost optimisation programme launched



Strong free cash flow and increased returns to shareholders enhanced by our new sustainable share buyback programme

6

#### **HYGIENE HIGHLIGHTS**

#### Broad-based growth<sup>1</sup>



Auto Dishwash

' +11%

LFL NR CAGR vs 2019



Surface & Disinfection

+10%

LFL NR CAGR vs 2019



Air Care

+4%

LFL NR CAGR vs 2019



**Fabric Additives** 

+5%

LFL NR CAGR vs 2019



Lavatory care

+9%

LFL NR CAGR vs 2019

#### Innovation driving category growth



Category creation

Household


penetration



Category creation + premiumisation



Premiumisation



Household penetration



Pack fill rate FY 2023

**Executing with excellence** 



Share of markets recognised as top tier by retail partners<sup>2</sup>

<sup>1 -</sup> Growth relates to main category brands (Finish, Lysol, Airwick and Vanish)

#### **HEALTH HIGHLIGHTS**

#### **Attractive categories**

















#### **Broadening shoulders of our brands**



Household penetration



Category creation + premiumisation



Premiumisation



Category creation

#### **Executing with excellence**



Prioritised supply activities



Invested in strong marketing programme



Improved ASEAN in market competitiveness

## **NUTRITION HIGHLIGHTS**

#### North America nutrition rebasing











Share of hospital contracts (2021: 30%)

#### Portfolio premiumisation









#### **Evolving regulatory environment**



Safety first, quality always



Operating with resilience in new environment



Future fit supply chain to support compliance and growth

#### **CLEAR PRIORITIES**



Win in market

+44% of core CMUs gaining / holding share

Working to get to or above **60% target** 



**Product** superiority

Leveraging data driven insights

Bringing new scientifically grounded innovations to consumers



**Executional** excellence

Across Sales, Supply and Marketing

Everywhere every day



Fixed cost optimisation

**Programme launched** 

Targeting 200bps of net revenue savings over the coming years



Grow EPS


Taking definitive steps towards sustainable EPS growth

Driven by our
earnings model and
supplemented by
ongoing share
buybacks programme

## WE HAVE AN ENDURING FRAMEWORK FOR VALUE CREATION



#### WE HAVE AN ENDURING FRAMEWORK FOR VALUE CREATION




+2% T0 +4%

- + MSD Hygiene and Health
- + Nutrition Rebasing

## **ON TRACK**

+ Second half weighted



2024 TARGETS

2x RETURNS IN 2024 VS 2019





# **JEFF CARR**

**Chief Financial Officer** 

#### **GROUP SUMMARY:** A YEAR OF PROGRESS

FY 2023



Volume

(4.3)%

Price/Mix

+7.8%

Q4 2023



Volume

(4.3)%

Price/Mix

+3.1%

FY 2023

Net revenue

£14,607M

IFRS net revenue growth: +1.1%

Adjusted operating profit (AOP)

£3,373M

23.1% AOP margin

Free cash flow

+11%

£2,258M

**Gross profit margin** 

60.0%

+220bps vs 2022

IFRS operating profit


£2,531M


**Adjusted diluted EPS** 


323.4P

-5.4% vs 2022

## **QUARTERLY VOLUME TRENDS BY GBU**







## **GROUP MARGINS:** GROSS MARGIN EXPANSION AND INCREASED BEI

£m	FY 2023	FY 2022	Change Actual FX	Change Constant FX
Net Revenue	14,607	14,453	+1.1%	+3.7%
LFL growth	+3.5%	+7.6%		
Gross Margin %	60.0%	57.8%	+220bps	
Brand Equity Investment	(1,908)	(1,712)	+11.4%	+13.2%
BEI %	13.1%	11.8%	(130)bps	
Other Costs	(3,479)	(3,210)	+8.4%	+10.3%
Other Costs %	23.8%	22.2%	(160)bps	
Adjusted Operating Profit	3,373	3,439	(1.9)%	+0.9%
Adjusted Operating Profit Margin	23.1%	23.8%	(70)bps	

#### **HYGIENE:** BROAD-BASED GROWTH

FY 2023



Volume

(6.0)%

Price/Mix

+11.1%

Q4 2023



Volume

(2.6)%

Price/Mix

+7.8%

**FY 2023** 

Net revenue £6,135

PY: £5,960m

**Adjusted** operating profit (AOP) £1,236M +4.7% vs 2022 at constant FX

**AOP** margin 20.1%

(30)bps vs 2022

## **HEALTH: STRONG GROWTH ACROSS OTC AND INTIMATE WELLNESS**

FY 2023



Volume

(0.3)%

Price/Mix

+5.3%

Q4 2023



Volume

(2.2)%

Price/Mix

+0.2%

**FY 2023** 

Net revenue £6,062M PY: £5,992m

**Adjusted** operating profit (AOP) £1,690M +6.3% vs 2022 at constant FX

AOP margin 27.9%

+40bps vs 2022

#### **NUTRITION: US NUTRITION REBASING**

FY 2023



Volume

(10.0)%

Price/Mix

+6.0%

Q4 2023



Volume

(14.3)%

Price/Mix

(0.5)%

**FY 2023** 

Net revenue £2,410M PY: £2,501m

**Adjusted** operating profit (AOP)


£447M

(22.4)% vs 2022 at constant FX

**AOP** margin 18.5%

(460)bps vs 2022

#### **US NUTRITION REBASING**




#### NUTRITION - NA VOLUME GROWTH OFFSET BY DVM MARKET CHALLENGES




DEVELOPING MARKETS VOLUME DECLINE IN LINE WITH MARKET DECLINES

#### ADJUSTED EPS – GROWTH IN AOP OFFSET BY TAX AND FX




## STRONG FREE CASH FLOW GENERATION

£m	FY 2023	FY 2022	Change
Adjusted operating profit	3,373	3,439	(66)
Depreciation, share-based payments and gain on disposal of fixed assets (net of proceeds)	585	521	64
Capital expenditure	(449)	(443)	(6)
Movement in working capital and provisions	(21)	(408)	387
Cash flow in relation to adjusting items	(45)	(38)	(7)
Interest paid	(263)	(209)	(54)
Tax paid	(922)	(831)	(91)
Free Cash Flow	2,258	2,031	227
Free Cash Flow Conversion	97%	83%	14%









# SHANNON EISENHARDT

**Chief Financial Officer Designate** 

## 2024 OUTLOOK AND GUIDANCE

**Group LFL net revenue growth** 

+2% T0 +4%

- MSD growth in Hygiene and Health
- MSD to HSD decline in Nutrition

#### Adjusted operating profit

# AOP GROWTH AHEAD OF NR GROWTH





Capex as % of net revenue

**3% - 3.5%** 



Adjusted tax rate

**25% - 26%** 

## 2024 REVENUE AND PROFIT GROWTH SECOND HALF WEIGHTED



#### HEALTH


Growth more back half weighted (Q1 23 OTC retailer inventory rebuild in Europe)



Low teens NR decline in H1 (lapping high prior year market shares)

Return to NR growth late in the year

## **LEVERAGE REDUCED**



#### CAPITAL ALLOCATION PRIORITIES



Investment in organic growth



Strong free cash conversion



Progressive dividend policy



Target single A credit rating (leverage at around 2.0x)



Manage the portfolio for value creation



**Return cash to shareholders** 

ONGOING SHARE BUYBACK PROGRAMME - WITH HEADROOM TO GROW

#### **INCREASED CASH RETURNS +24%**

#### FREE CASH FLOW



Strong free cash generation

+11% in 2023

#### **NET DEBT**





Target single A credit rating

Leverage reduced from 2.1x to 1.9x in 2023

#### **DIVIDENDS**



Progressive dividend policy

**+5%** in 2023

#### **SHARE BUYBACKS**




New £1bn 12-month share buyback programme commenced

£0.2bn in 2023

**Ongoing** programme with headroom to grow

#### WE HAVE AN ENDURING FRAMEWORK FOR VALUE CREATION




+2% T0 +4%

- + MSD Hygiene and Health
- + Nutrition Rebasing

## **ON TRACK**

+ Second half weighted



2024 TARGETS

2x RETURNS IN 2024 VS 2019



# **KRIS LICHT**

**Chief Executive Officer** 



## **RECAP - KEY MESSAGES**



A year of progress in 2023



**Clear priorities** 



**Enduring framework** for value creation